Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer

• DOI: 10.3389/fimmu.2022.954616
• Publication Date: 2022-07-25T14:08:02Z
• Authors: Zhao Zhang; Yongbo Yu; Peng Li; Meilan Wang; Wei Jiao; Ye Liang; Haitao Niu
• Keywords: Gene signature; Reprogramming

Background Epithelial-mesenchymal transition (EMT), one leading reason of the dismal prognosis bladder cancer (BLCA), is closely associated with tumor invasion and metastasis. We aimed to develop a novel immune−related gene signature based on different EMT metabolic status predict BLCA. Methods Gene expression clinical data were obtained from TCGA GEO databases. Patients clustered metabolism scores calculated by ssGSEA. The immune-related differentially expressed genes (DEGs) between two clusters most obvious differences used construct LASSO Cox analysis. Time-dependent receiver operating characteristic (ROC) curves Kaplan–Meier utilized evaluate in training validation cohorts. Finally, function AHNAK NFATC1 BLCA cell lines explored cytological experiments. Results Based results ssGSEA, patients divided into three clusters, among which cluster 1 3 had completely opposite status. significantly worse than 1. Immune-related DEGs selected predictive 14 genes. High-risk poorer prognosis, lower proportions CD8 + T cells, higher carbohydrate metabolism, less sensitivity chemotherapy immunotherapy. Overexpression or promoted proliferation, migration T24 UMUC3 cells. Silencing ANHAK could effectively inhibit Conclusion established immune may act as promising model for generating accurate predicting their status, thus guiding treatment patients.